Holen Sie sich die Stockscreener-App
123.52
1.96%
2.37
Handel nachbörslich:
123.52
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
How Axsome Therapeutics Inc. stock compares to market leaders2025 Buyback Activity & Precise Buy Zone Tips - newser.com
What candlestick patterns are forming on Axsome Therapeutics Inc.Analyst Downgrade & Precise Swing Trade Entry Alerts - newser.com
Axsome Therapeutics Inc. stock volume spike explainedShare Buyback & AI Powered Market Entry Ideas - newser.com
Will Axsome Therapeutics Inc. (19X) stock deliver stable dividendsMarket Movers & Fast Entry Momentum Trade Alerts - newser.com
Is Axsome Therapeutics Inc. stock gaining market shareDip Buying & Fast Gain Swing Trade Alerts - newser.com
Axsome Therapeutics Inc. stock trend forecast2025 Geopolitical Influence & Proven Capital Preservation Methods - newser.com
Tools to assess Axsome Therapeutics Inc.’s risk profileQuarterly Risk Review & Long-Term Capital Growth Strategies - newser.com
Axsome Therapeutics (AXSM) Stock Analysis: Unpacking A Potential 45% Upside In Biotech - DirectorsTalk Interviews
Axsome Therapeutics, Inc. $AXSM Shares Sold by Blair William & Co. IL - MarketBeat
What is William Blair's Estimate for AXSM FY2026 Earnings? - MarketBeat
Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Grows Stock Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
IFP Advisors Inc Sells 4,096 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Q3 EPS Estimate for Axsome Therapeutics Reduced by Analyst - MarketBeat
Can trapped investors hope for a rebound in Axsome Therapeutics Inc.Gap Up & Verified Stock Trade Ideas - newser.com
Axsome Therapeutics' Strong Growth And Expanding Pipeline: Why I Assign A Buy Rating - Seeking Alpha
Axsome Therapeutics (NASDAQ:AXSM) CEO Sells $1,590,330.30 in Stock - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) CEO Sells $1,518,062.16 in Stock - MarketBeat
Herriot Tabuteau Sells 19,220 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Axsome Therapeutics (AXSM): Exploring Valuation After Recent Share Price Stability - Yahoo Finance
Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community - The Manila Times
Real time social sentiment graph for Axsome Therapeutics Inc.Weekly Profit Recap & AI Driven Price Forecasts - newser.com
1 in 5 U.S. adults affected — Axsome Recognizes Mental Illness Awareness Week and shares NAMI resources - Stock Titan
Axsome therapeutics CEO sells $5.4m in shares By Investing.com - Investing.com Canada
Axsome therapeutics CEO sells $5.4m in shares - Investing.com
Leerink Partnrs Issues Positive Forecast for AXSM Earnings - MarketBeat
Axsome Therapeutics Schedule Third Quarter 2025 Financial Results Announcement and Conference Call - Quiver Quantitative
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3 - The Manila Times
Knights of Columbus Asset Advisors LLC Grows Stake in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Q3 2025 Results Nov 3: Axsome Therapeutics to Report Results and Host 8:00 AM ET Conference Call; Webcast - Stock Titan
Is Axsome Therapeutics Inc 19X a good long term investmentVolatility Adjusted Trading & Free Trading Psychology Sessions - earlytimes.in
Can Axsome Therapeutics Inc. stock withstand economic slowdownWeekly Trade Analysis & Verified Momentum Stock Alerts - newser.com
Will Axsome Therapeutics Inc. (19X) stock outperform global peersM&A Rumor & High Conviction Trade Alerts - newser.com
J. Safra Sarasin Holding AG Purchases 9,998 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Meet Herriot Tabuteau, The Haitian-Born Doctor Whose Brain Disorder Medications Turned Into A $6 Billion Empire - Black Enterprise
What is B. Riley's Estimate for AXSM Q3 Earnings? - MarketBeat
Piper Sandler Maintains Overweight on Axsome (AXSM), Sees Growth in AD-Agitation - Yahoo Finance
Migraine Market Growth to Surge During Forecast Period (2024–2034), Says DelveInsight | Eli Lilly and Company, Teva Pharmaceuticals, Axsome Therapeutics, AEON Biopharma, Inc., Charleston Laboratories - Barchart.com
Axsome Therapeutics (NASDAQ:AXSM) Upgraded by B. Riley to Strong-Buy Rating - MarketBeat
B. Riley Securities Initiates Coverage of Axsome Therapeutics (AXSM) with Buy Recommendation - Nasdaq
AXSM: New 'Buy' Rating from B. Riley Securities with $179 PT | A - GuruFocus
How Axsome Therapeutics Inc. (19X) stock trades after rate cuts2025 Support & Resistance & Intraday High Probability Setup Alerts - newser.com
B. Riley Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $179 - 富途牛牛
Axsome Therapeutics Stock Slips On Q4 Profit Miss, But Retail Takes It In Stride - MSN
H.C. Wainwright maintains Axsome stock Buy rating, $190 target - MSN
14 Best Biotech Stocks to Buy Right Now - Insider Monkey
Can Auvelity Drive Axsome's Growth Through the Rest of 2025? - The Globe and Mail
Obstructive Sleep Apnea Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Apnimed, Eli Lilly and Company, Axsome Therapeutics/Jazz Pharmaceuticals, Bioprojet Pharma - Barchart.com
Obstructive Sleep Apnea Market Insights Highlight Expanding - openPR.com
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):